The fundamental task of the cell cycle is to ensure that DNA is faithfully replicated once during S phase and that identical chromosomal copies are distributed equally to two daughter cells during M phase (1) . The machinery for DNA replication and chromosome segregation is insulated from interruption by extracellular signals, and its essential and autonomous nature implies that damage to the pivotal components would be highly debilitating, if not fatal, to cells. Therefore, genes commanding these processes should not be frequent targets of mutation, deletion, or amplification in cancer.
Oncogenic processes exert their greatest effect by targeting particular regulators of GI phase progression (2, 3) . During the G, phase, cells respond to extracellular signals by either advancing toward another division or withdrawing from the cycle into a resting state (Go) (4, 5) . Unlike transit through the S, G2, and M phases, G progression normally relies on stimulation by mitogens and can be blocked by antiproliferative cytokines. Cancer (4, 5) . An appreciation of restriction point control is central to our understanding of how and why cancer cells continuously cycle.
Restriction Point Control and the G1-S Transition
Passage through the restriction point and entry into S phase is controlled by cyclindependent protein kinases (CDKs) that are sequentially regulated by cyclins D, E, and A ( Fig. 1) . In general, CDK activity requires cyclin binding, depends on both positive and negative regulatory phosphorylations (6) , and can be constrained by at least two families of CDK inhibitory proteins (7) .
D-type cyclins act as growth factor sensors, with their expression depending more on extracellular cues than on the cell's position in the cycle (8) . As cells enter the cycle from quiescence (GO), one or more D-type cyclins (DI, D2, and D3) are induced as part of the delayed early response to growth factor stimulation, and both their synthesis and assembly with their catalytic partners, CDK4 and CDK6, depend on mitogenic stimulation (5 (9) . The four known 15-to pl5INK4h, p18INK4c, and pl9INK4d) bind and inhibit CDK4 and CDK6, but not other CDKs. Like the three D-type cyclins, the INK4 genes are expressed in distinct tissue-specific pattems, suggesting that they are not strictly redundant.
A loss of cyclin DI-dependent kinase activity before the restriction point prevents many cultured cell lines from entering S phase, but its absence later in the cell cycle is without effect (10, 11) . Hence, cyclin D-dependent kinases must phosphorylate some substrate or substrates whose modification is required for G0 exit, and the retinoblastoma tumor suppressor protein (RB) is one such target (12) . Notably, cyclin D-dependent kinases are dispensable for passage through the restriction point in cultured cells that lack functional RB, and in this setting, ectopic expression of INK4 proteins does not induce GI phase arrest (13) . Thus, INK4 proteins inhibit cyclin D-dependent kinases that, in turn, phosphorylate RB (Fig. 2) . Disruption of this "RB pathway" is important in cancer.
RB and other RB-like proteins (pI30, plO7) control gene expression mediated by a family of heterodimeric transcriptional regulators, collectively termed the E2Fs (14, 15) , which can transactivate genes whose products are important for S phase entry (14, 16) (Fig. 2) . In its hypophosphorylated form, RB binds to a subset of E2F complexes, converting them to repressors that constrain expression of E2F target genes (17) . Phosphorylation of RB frees these E2Fs, enabling them to transactivate the same genes, a process initially triggered by the cyclin D-dependent kinases (5, 12, 13) and then accelerated by the cyclin E-CDK2 complex (18) (19) (20) (Fig. 2) .
In proliferating cells, the expression of cyclin E is normally periodic and maximal at the GI-S transition (Fig. 1) , and throughout this interval, cyclin E enters into active complexes with its catalytic partner CDK2. Because the cyclin E gene is itself E2F-responsive, cyclin E-CDK2 acts through positive feedback to facilitate progressive rounds of RB phosphorylation and E2F release (16, 19) (Fig. 2) . In addition, E2F-1 stimulates its own transcription. Positive cross-regulation of E2F and cyclin E produces a rapid rise of both activities as cells approach the G1-S boundary. In concert with the irreversible commitment to enter S phase, RB inactivation shifts from being mitogen-dependent (cyclin D-driven) to mitogen-independent (cyclin E-driven). Inactivation of RB by phosphorylation or by direct genetic damage to the RB gene itself shortens the GI phase, reduces cell size, and decreases, but does not eliminate, the cell's requirements for mitogens and adhesive signals (11, (21) (22) (23) . Because RBnegative cells retain some requirements for growth factors, events in addition to RB phosphorylation must contribute to restriction point control.
Cyclin A-and cyclin B-dependent kinases probably maintain RB in its hyperphosphorylated state as the cycle moves ahead (Fig. 1 (23, 25) . Substrates for cyclin E-CDK2 and cyclin A-CDK2 could include proteins at replication origins ( Fig. 2 ) whose phosphorylation might promote DNA synthesis or prevent reassembly of preinitiating complexes (1, 26) .
Once cells enter S phase, the timely inactivation of cyclin E and E2F activities may be equally crucial for cell cycle progression. Rapid turnover of cyclin E is mediated by ubiquitin-dependent proteolysis, and its phosphorylation by its own catalytic partner, CDK2, signals its destruction (27) . E2F-1 transactivation activity also decreases once cells enter S phase, as cyclin A-CDK2 complexes accumulate (Fig. 1) . Cyclin A-CDK2 binds to the RB-regulated E2Fs and phosphorylates one of their heterodimeric components (DP-1), thereby precluding DNA binding (28) . Because the cyclin E-CDK2 complex lacks this function, the reversal of E2F-mediated transactivation during S phase depends on the appearance of cyclin A-CDK2.
Cyclin D-, E-, and A-dependent kinases are negatively regulated by a distinct family of CDK inhibitors that include at least three proteins: p21ClI, p27KIP, and p57KIP2 (29) (30) (31) . The single most remarkable feature in relation to cancer is the inducibility of the CIPJ gene by the tumor suppressor p53 [(29) , and see below], although these genes also respond to many other types of stimuli during terminal differentiation (7) . KIP] may be the most directly involved in restriction point control. In quiescent cells, p27KIP1 levels are high, but once cells enter the cycle, they fall ( Fig. 1) (32) . Residual p27KIPI is sequestered into complexes with excess cyclin D-CDK complexes (31, 32) , alleviating p27KIPl-mediated repression of cyclin E-CDK2 and cyclin A-CDK2 activity in cycling cells. The level of p27KIPI is largely controlled by translational (33) and posttranslational (34) mechanisms, and because its turnover can be accelerated by cyclin E-CDK2-mediated phosphorylation (35) , cyclin E-CDK2 and p27KIPI may oppose each other's function (Fig. 2) . When proliferating fibroblasts are deprived of serum mitogens, synthesis of p27KIPI not only increases, but the inhibitor is released from cyclin D-CDK complexes as cyclin D is degraded. The loss of cyclin D-dependent kinase activity coupled with p27KIPl-mediated inhibition of CDK2 induces arrest in GI-Go within a single cycle (Fig. 1 ). Antisense inhibition of p27 synthesis in cycling cells can prevent them from becoming quiescent (36) . Mice nullizygous for the gene encoding p27 grow faster than littermate controls and exhibit frank organomegaly, with all tissues containing increased numbers of smaller cells (37 (6) . p27 levels are high in quiescent cells, fall in response to mitogenic stimulation, remain at lower threshold levels in proliferating cells, and increase again when mitogens are withdrawn. In proliferating cells, most p27 is complexed with cyclin D-CDK complexes (7, 31 (-50%) and esophageal (-30%) carcinomas (3, 7) . Reciprocally, a mutation in CDK4 that prevents its interaction with p16 has been found in melanoma (41) (INK4a-1-) mice.
These animals spontaneously develop a spectrum of different tumors by 6 months of age, with the rate of tumor formation accelerated in response to carcinogen treatment (42) . Cultured INK4a-/-embryo fibroblasts do not senesce, and unlike their wild-type counterparts, they can be transformed by oncogenic RAS alone. Although the INK4a locus also encodes a second, potentially contributory protein (pl9ARF) from an alternative reading frame (43) , the weight of current evidence favors the primary involvement of pl6INK4a in tumorigenesis (42) .
Inactivation of RB itself is the sine qua non of retinoblastoma (44) and (14, 15) ], E2F "activity" is shown for simplicity. E2F triggers the expression of dihydrofolate reductase (DHFR), thymidine kinase (TK), thymidylate synthase (TS), DNA polymerase-o. (POL), CDC2, cyclin E and possibly cyclin A, and E2F-1 itself. This establishes a positive feedback loop promoting RB phosphorylation by cyclin E-CDK2, contributing to the irreversibility of the restriction point transition and ultimately making it mitogen-independent. In parallel, cyclin E-CDK2 may oppose the inhibitory action of p27KIPl by phosphorylating it (35) . This allows cyclin A-CDK2 and possibly cyclin E-CDK2 to start S phase. Possible CDK substrates include those of the origin-recognition complex (ORC), minichromosome maintenance proteins (MCMs), and CDC6, all of which assemble into preinitiation complexes (26) . Once cells enter S phase, cyclin A-CDK2 phosphorylates DP-1 and inhibits E2F binding to DNA (28) . Like p27, p53-inducible p21 c/PR can induce G1 arrest by inhibiting the cyclin D-, E-, and A-dependent kinases (29, 30) . In contrast, INK4 proteins antagonize only the cyclin D-dependent kinases (9) . The 
Other G1-S Regulators in Cancer
Although the E2F genes are the apparent targets of the RB pathway, their overexpression, mutation, or inactivation has not as yet been reported in human cancers. In mice, the elimination of both wild-type E2F1 alleles leads to developmental defects in some tissues and to tumors in others (47) , but in humans, alterations in a single E2F complex might be adequately compensated.
Alterations in the cyclin E and cyclin A genes in human cancers also appear to be rare (3) . Very few cases of cyclin E amplification have been reported in established tumor cell lines, and there is only one instance in which the cyclin A gene was found to be altered in a hepatoma (48) . Nonetheless, sustained overexpression of cyclin E is tolerated under experimental conditions (21) , and the protein is aberrantly overexpressed in carcinomas of the breast, stomach, colon, and endometrium, and in some adult acute lymphocytic leukemias (49) . Overexpression of cyclin E could result from its failure to undergo ubiquitinmediated degradation. Homozygous inactivation of the KIP] and CIP1 genes has not been reported either, but reduction in p27KI''' levels in a subset of colon and breast cancers correlates with poor prognosis (35, 50 (52) and is an archetypal checkpoint regulator. Although it is not essential for normal mouse development (53) , one of its roles is to ensure that, in response to genotoxic damage, cells arrest in GI and attempt to repair their DNA before it is replicated (54) . Although p53 is ordinarily a very short-lived protein, it is stabilized and accumulates in cells undergoing DNA damage or in those responding to certain forms of stress (54) (55) (56) . The precise signal transduction pathway that senses DNA damage and recruits p53 has not been elucidated, but is likely to include genes like ATM [mutated in ataxia telangiectasia (AT)I (57) . The p53 protein functions as a transcription factor, and cancer-related mutations cluster in its DNA binding domain (55) . MDM-2, a p53-inducible and amplifiable proto-oncogene product, neutralizes p53 action by binding to and inhibiting its transactivating domain (58) . The gene encoding the CDK inhibitor p21l1"'1 is another target of p53-mediated regulation (29) and is at least partially responsible for p53-mediated GI arrest (59) .
When treated with DNA-damaging drugs, cells lacking p2lClh appear to undergo repeated S phases, possibly reflecting aberrations in controls linking the completion of S phase with mitosis (60) .
Ionizing radiation not only triggers arrest at the G,-S checkpoint but it also slows S phase and blocks progression in G2, allowing additional time for the repair of chromosome breaks before entry into mitosis (51) . The loss of p53 predisposes cells to drug-induced gene amplification and decreases the fidelity of mitotic chromosome transmission (61) . Duplication of the centrosome normally begins at the G -S boundary, but in the absence of p53, multiple centrosomes appear to be generated in a single cell cycle, ultimately resulting in aberrant chromosomal segregation during mitosis (62) . Barring changes so severe as to precipitate mitotic catastrophe, the resulting genetic instability leads to changes in chromosome number and ploidy, further increasing the probability that such cells will more rapidly evolve toward malignancy by escaping immune surveillance, tolerating hypoxia, and becoming angiogenic, invasive, metastatic, and, ultimately, drug resistant in the face of chemotherapy.
In some cell types, p53 induces apoptosis when overexpressed (63) and is required for apoptosis in response to severe DNA damage, chemotherapeutic drugs, or MYC or EIA overexpression (64) . Launching this apoptotic program does not depend on p2l (59) , and p53 may directly activate death genes, such as BAX, or down-regulate survival genes, such as BCL-2 (65) . Hence, GI arrest and apoptosis appear to be alternative p53-induced outcomes. Cell suicide is arguably the most potent natural defense against cancer, because it eliminates premalignant cells that enter S phase inappropriately after genetic sabotage of restriction point controls (64, 66) . Consistent with the idea that p53-induced p2l"" can limit RB hyperphosphorylation (Fig. 2) , loss of RB function can bypass p53-mediated GC arrest (67) . However, overexpression of E2F-1 not only drives quiescent cells to synthesize DNA, but it induces p53-dependent apoptosis (68) . Cooperation between the RB and p53 pathways likely determines whether p53 induces G1 arrest or apoptosis in response to DNA damage, with the loss of RB tilting the balance toward the latter. In cells that have sustained lesions in the RB pathway, there could be a strong selection for the loss of normal p53 (66) .
A Final Accounting
Of the more than 100 proto-oncogenes and tumor suppressor genes that have been identified, most function in signal transduction to mimic effects of persistent mitogenic stimulation, thereby uncoupling cells from environmental controls. Their signaling pathways converge on the machinery controlling passage through the GC phase, inducing GI cyclins, overriding CDK inhibitors, preventing cell cycle exit, and ultimately perturbing checkpoint controls. Some transcription factors such as MYC play important roles in cell cycle progression, directly reg-SCIENCE * VOL. 274 * 6 DECEMBER 1996 ulating CDC25 phosphatases that control CDK activity (69) and, probably indirectly, cyclin expression as well (70) . Other transcription factors, including many encoded by genes that are targeted by cancer-specific chromosomal translocations, instead seem to control lineage-specific differentiation and developmental decisions (71) , including apoptosis (72) .
Despite this plethora of oncogenes, an accounting indicates that pathways dominated by two tumor suppressor genes, RB and p53, are the most frequently disrupted in cancer cells. What about the RB pathway? The discovery of RB in the context of familial retinoblastoma pointed toward its specialized role in the retina (44) . Yet, RB's biochemical behavior connoted a more generalized function during the cell cycle, and so it seemed surprising that it was completely dispensable throughout much of mouse development (45) . RB therefore appears to be unnecessary for the cell cycle per se, and even the eventual lethality imposed by its loss during gestation may not be due to cell autonomous mechanisms (73) In children who inherit a mutant RB allele, retinal tumors lacking both copies of the gene appear early in life with almost 100% penetrance, emphasizing the particular susceptibility of retinoblasts to RB loss (19, 44) . The overall incidence of cancer in persons under 15 years of age is one-thirtieth that of the population as a whole, and even in children, familial and sporadic retinoblastomas are rare (together, 3% of all pediatric tumors) (77) . Indeed, most pediatric cancers consist of leukemias, lymphomas, and sarcomas, or arise elsewhere in the nervous system. Thus, although retinoblastoma provided the historical basis for Knudson's now classic "two-hit hypothesis" for tumor suppression (44) , the very short developmental history of these tumors in humans [and of pituitary tumors in RB+'-mice (45) ] is atypical of cancer in general. The loss of RB or INK4a in childhood tumors need not stem from inherited defects because their inactivation is also observed in sporadic pediatric cancers, with disruption of RB function occurring in osteosarcomas and that of p16 in a high percentage of childhood T cell leukemias and glioblastomas (3, 7) .
In contrast, more than 80% of adult cancers in the United States are carcinomas (tumors arising from basal epithelial cells of ectodermal or endodermal origin), and 8% are hematopoietic with a higher preponderance of myeloid leukemia than is observed in children (77) . Carcinomas are rare in persons under age 30, rising exponentially in incidence thereafter, and their appearance with increasing age emphasizes the importance of cumulative exposure to environmental carcinogens in their induction. The cardinal property of the affected target tissues is that they undergo replacement throughout life. In this setting, stem cells must continuously enter the cell cycle to produce differentiated progeny, and over time, they are vulnerable to carcinogenic attack. Cyclin DI, p16, and RB figure most prominently here (78) . In terms of overall cancer incidence per annum, RB inactivation is at least 50 (79) , is also compatible with an inducible surveillance function. RB-negative tumor cells, but not fibroblasts from RB-'-mice, express uncharacteristically high levels of p16 (7, 9, 13) 
